Navigation Links
ChromaDex to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:9/6/2011

IRVINE, Calif., Sept. 6, 2011 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC) announced today that its Chief Executive Officer, Frank L. Jaksch, Jr., will be presenting the company's business strategy and growth opportunities at the 2011 Rodman & Renshaw Annual Global Investment Conference. The event will be held September 11-13, 2011 at the Waldorf Astoria in New York City.

ChromaDex is scheduled to make its presentation on Tuesday, September 13th at 11:30 a.m. local time. The company's presentation is currently available on its website, www.chromadex.com. For further details about the conference, please visit http://www.rodmanandrenshaw.com/conferences?id=162.

For more information about ChromaDex Corporation, visit www.chromadex.com and www.pteropure.com.

About ChromaDex®

ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights.  

ChromaDex Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Investor Inquiries:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
John@Liviakis.com

ChromaDex Contact
Laura Carney
Administrative Assistant
949-419-0288
laurac@chromadex.com

ChromaDex Media Inquiries:
Chandler Chicco Agency
Kerry Sinclair, Media Specialist
310-309-1031
ksinclair@ccapr.com


'/>"/>
SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ChromaDex Announces Second Quarter 2008 Financial Results
2. ChromaDex Announces 2008 Year End Financial Results
3. ChromaDex Launches pTeroPure Pterostilbene
4. ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene
5. ChromaDex Names Pharmaceutical Industry Veteran William F. Spengler as President
6. ChromaDex Appoints Curtis Lockshin, Ph.D., to its Board of Directors
7. InterMune to Present at Canaccord Adams Conference
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
9. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
10. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
11. Bionovo to Present at Canaccord Adams Global Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):